Cytokine-based therapies hold immense promise, but their development has been anything but simple. From early breakthroughs to unforeseen hurdles, the field has faced complex challenges in safety, efficacy, and clinical translation. Rather than seeing these obstacles as setbacks, the cytokine community came together to understand, refine, and innovate – turning challenges into opportunities together.

The 6th Cytokine-Based Drug Development Summit united the most influential leaders from Candel, Deka Biosciences, Regeneron, Sanofi, ModeX, OSE, and more to navigate the key translational and therapeutic index challenges —from overcoming systemic toxicities and improving specificity to engineering next-generation cytokine therapeutics with pro-drug, pulsed, targeted, and multi-specific immunomodulation strategies.

Participants engaged in intimate discussions and gained world-class insights through interactive workshops, roundtable discussions, and presentations to address the complexities of cytokine therapies and influence the future of immunotherapy.

At this pivotal time for cytokine drug developers, the summit drove innovation and helped break down barriers associated with systemic toxicity by improving the specificity and delivery of cytokine-based drugs.